Prior to founding Nextech Venture AG (today Nextech Invest AG) in 1998, Dr Scheidegger was managing director and board member of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. He has held previous roles as the managing director of the Swiss Supercomputing Center (CSCS) and directed an international drug-discovery project at Ciba-Geigy (today Novartis), Japan. In 1998, he was involved in launching the first Swiss national business plan competition, venture97. Dr Scheidegger holds a PhD in microbiology and biochemistry from the University of Basel, Switzerland and did his postdoctoral research training in enzymology at the University of Kyoto, Japan. Dr Scheidegger completed an executive training program (TGM) at Harvard Business School, USA.
Currently, Alfred Scheidegger is on the board of directors at Cleave Biosciences, Molecular MD (observer), and Dottikon ES Holding. Past board representations include Agensys (acquired by Astellas), Ganymed Pharmaceuticals (acquired by ATS), MacroGenics (NASDAQ: MGNX), Sunesis Pharmaceuticals (NASDAQ: SNSS), TetraLogic Pharmaceuticals (NASDAQ: TLOG), and Tracon Pharmaceuticals (NASDAQ: TCON).
Mr. Scheidegger is responsible for the following Nextech portfolio companies:
Tracon Pharmaceuticals, MolecularMD , Cleave Biosciences
Portfolio companies Mr. Scheidegger has been involved with previously:
TetraLogic Pharmaceuticals, TeLoRmedix, Sunesis Pharmaceuticals, Palyon Medical, MacroGenics, Ganymed Pharmaceuticals, Agensys